Study design (Participants, Sample size and Sampling)
BLIND, COMPLICATION
This study was conducted as an educational randomized controlled trial (single blind) on patients with MS receiving injectable immunomodulatory drugs referring to the County MS Clinic in the city of Tehran, Iran from 2021 to 2022.Prospectively registered at 12-Aug-2021, The sample size was calculated based on previous study Dashti et al. [In this study having means of 35.42 and 59.51 and standard deviations of 11.36 and 9.88 for the intervention group before and after the intervention for self- care related complication in women with MS respectively in Dashti et al. [For sampling, a list of all patients was obtained from MS Clinic of hospital (3000 patients). Out of the patients having medical records in the clinic, 100 patients were selected through systematic sampling and were randomly (every other person) assigned to the intervention (For systematic sampling after determine target sample size (100 patients), we calculated interval, k, by dividing total estimated population size (patients MS) by sample size. This can be a rough estimate rather than an exact calculation. In this way 3000 MS present in clinic and based on the sample size 100therefore our sampling interval k thus equals 3000/100 = 30.Then selected the sample and collect data based on the list of population MS, randomly select a starting point on our list, (based on the table of random numbers, a starting point was selected for sampling) and from there, selected every kth member of the population based on inclusion criteria to include sample.